• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2Δ30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain.与rDEN2Δ30(汤加/74)实验性感染相关的细胞免疫模式支持其作为人类登革病毒攻击株的适用性。
J Virol. 2017 Mar 29;91(8). doi: 10.1128/JVI.02133-16. Print 2017 Apr 15.
2
The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes.由减毒活四价登革热疫苗诱导的人类 CD8+ T 细胞应答针对高度保守的表位。
J Virol. 2015 Jan;89(1):120-8. doi: 10.1128/JVI.02129-14. Epub 2014 Oct 15.
3
Human CD4 T Cell Responses to an Attenuated Tetravalent Dengue Vaccine Parallel Those Induced by Natural Infection in Magnitude, HLA Restriction, and Antigen Specificity.人类CD4 T细胞对一种减毒四价登革热疫苗的反应在强度、HLA限制和抗原特异性方面与自然感染所诱导的反应相似。
J Virol. 2017 Feb 14;91(5). doi: 10.1128/JVI.02147-16. Print 2017 Mar 1.
4
Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection.CD4+ 与 CD8+ T 淋巴细胞在登革病毒感染中对病毒成分的差异靶向作用。
J Virol. 2013 Mar;87(5):2693-706. doi: 10.1128/JVI.02675-12. Epub 2012 Dec 19.
5
T Cell Responses Induced by DNA Vaccines Based on the DENV2 E and NS1 Proteins in Mice: Importance in Protection and Immunodominant Epitope Identification.基于登革热病毒 2 型 E 和 NS1 蛋白的 DNA 疫苗在小鼠中诱导的 T 细胞反应:在保护和免疫显性表位鉴定中的重要性。
Front Immunol. 2019 Jul 3;10:1522. doi: 10.3389/fimmu.2019.01522. eCollection 2019.
6
Dengue virus-specific CD4+ and CD8+ T lymphocytes target NS1, NS3 and NS5 in infected Indian rhesus macaques.登革病毒特异性 CD4+和 CD8+T 淋巴细胞靶向感染印度恒河猴的 NS1、NS3 和 NS5。
Immunogenetics. 2012 Feb;64(2):111-21. doi: 10.1007/s00251-011-0566-0. Epub 2011 Sep 1.
7
Antibody Epitopes Identified in Critical Regions of Dengue Virus Nonstructural 1 Protein in Mouse Vaccination and Natural Human Infections.在小鼠疫苗接种和人类自然感染中登革病毒非结构蛋白1关键区域鉴定出的抗体表位
J Immunol. 2017 May 15;198(10):4025-4035. doi: 10.4049/jimmunol.1700029. Epub 2017 Apr 5.
8
Rapid Induction and Maintenance of Virus-Specific CD8 T and CD4 T Cells Following Protective Vaccination Against Dengue Virus Challenge in Humans.在人类接种登革热病毒疫苗以预防病毒感染后,迅速诱导和维持病毒特异性 CD8 T 和 CD4 T 细胞。
Front Immunol. 2020 Mar 24;11:479. doi: 10.3389/fimmu.2020.00479. eCollection 2020.
9
Characterization of Magnitude and Antigen Specificity of HLA-DP, DQ, and DRB3/4/5 Restricted DENV-Specific CD4+ T Cell Responses.描述登革热病毒特异性 CD4+ T 细胞反应的幅度和抗原特异性与 HLA-DP、DQ 和 DRB3/4/5 的相关性。
Front Immunol. 2019 Jul 5;10:1568. doi: 10.3389/fimmu.2019.01568. eCollection 2019.
10
Immunodominant Dengue Virus-Specific CD8+ T Cell Responses Are Associated with a Memory PD-1+ Phenotype.免疫显性登革病毒特异性CD8 + T细胞反应与记忆性PD-1 +表型相关。
J Virol. 2016 Apr 14;90(9):4771-4779. doi: 10.1128/JVI.02892-15. Print 2016 May.

引用本文的文献

1
Regional Variation of the CD4 and CD8 T Cell Epitopes Conserved in Circulating Dengue Viruses and Shared with Potential Vaccine Candidates.循环登革热病毒中和表位和潜在候选疫苗的 CD4 和 CD8 T 细胞表位的区域差异。
Viruses. 2024 May 5;16(5):730. doi: 10.3390/v16050730.
2
Flavivirus genome recoding by codon optimisation confers genetically stable in vivo attenuation in both mice and mosquitoes.通过密码子优化使黄病毒基因组重新编码可赋予其在小鼠和蚊子体内稳定的遗传减毒特性。
PLoS Pathog. 2023 Oct 26;19(10):e1011753. doi: 10.1371/journal.ppat.1011753. eCollection 2023 Oct.
3
Controlled Human Infection Models To Accelerate Vaccine Development.控制人体感染模型以加速疫苗开发。
Clin Microbiol Rev. 2022 Sep 21;35(3):e0000821. doi: 10.1128/cmr.00008-21. Epub 2022 Jul 6.
4
A Novel Orf Virus D1701-VrV-Based Dengue Virus (DENV) Vaccine Candidate Expressing HLA-Specific T Cell Epitopes: A Proof-of-Concept Study.一种基于新型口疮病毒D1701-VrV的表达HLA特异性T细胞表位的登革病毒(DENV)候选疫苗:概念验证研究。
Biomedicines. 2021 Dec 8;9(12):1862. doi: 10.3390/biomedicines9121862.
5
Immunotranscriptomic profiling the acute and clearance phases of a human challenge dengue virus serotype 2 infection model.免疫转录组学分析人类登革热病毒 2 型感染模型的急性期和清除期。
Nat Commun. 2021 May 24;12(1):3054. doi: 10.1038/s41467-021-22930-6.
6
Identification and Characterization of CD4 T Cell Epitopes after Shingrix Vaccination.欣格来福接种后 CD4+T 细胞表位的鉴定和特征分析。
J Virol. 2020 Nov 23;94(24). doi: 10.1128/JVI.01641-20.
7
Safety and Immunogenicity of an AS03-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized Study.AS03 佐剂的四价灭活登革热病毒疫苗在不同时间间隔接种于健康美国成年人的安全性和免疫原性:一项 1/2 期随机研究。
Am J Trop Med Hyg. 2020 Jul;103(1):132-141. doi: 10.4269/ajtmh.19-0738. Epub 2020 Apr 23.
8
Human T Cell Response to Dengue Virus Infection.人类对登革热病毒感染的 T 细胞反应。
Front Immunol. 2019 Sep 4;10:2125. doi: 10.3389/fimmu.2019.02125. eCollection 2019.
9
Characterization of Magnitude and Antigen Specificity of HLA-DP, DQ, and DRB3/4/5 Restricted DENV-Specific CD4+ T Cell Responses.描述登革热病毒特异性 CD4+ T 细胞反应的幅度和抗原特异性与 HLA-DP、DQ 和 DRB3/4/5 的相关性。
Front Immunol. 2019 Jul 5;10:1568. doi: 10.3389/fimmu.2019.01568. eCollection 2019.
10
Antigenic cross-reactivity between Zika and dengue viruses: is it time to develop a universal vaccine?寨卡病毒和登革热病毒之间的抗原交叉反应:是否是时候开发通用疫苗了?
Curr Opin Immunol. 2019 Aug;59:1-8. doi: 10.1016/j.coi.2019.02.001. Epub 2019 Mar 15.

本文引用的文献

1
Human CD4 T Cell Responses to an Attenuated Tetravalent Dengue Vaccine Parallel Those Induced by Natural Infection in Magnitude, HLA Restriction, and Antigen Specificity.人类CD4 T细胞对一种减毒四价登革热疫苗的反应在强度、HLA限制和抗原特异性方面与自然感染所诱导的反应相似。
J Virol. 2017 Feb 14;91(5). doi: 10.1128/JVI.02147-16. Print 2017 Mar 1.
2
HLA-DRB1 Alleles Are Associated With Different Magnitudes of Dengue Virus-Specific CD4+ T-Cell Responses.HLA - DRB1等位基因与不同程度的登革病毒特异性CD4 + T细胞反应相关。
J Infect Dis. 2016 Oct 1;214(7):1117-24. doi: 10.1093/infdis/jiw309. Epub 2016 Jul 20.
3
EPIDEMIOLOGY. Countering the Zika epidemic in Latin America.流行病学。应对拉丁美洲的寨卡疫情。
Science. 2016 Jul 22;353(6297):353-4. doi: 10.1126/science.aag0219. Epub 2016 Jul 14.
4
The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model.TV003 减毒活登革热疫苗在人体挑战模型中可引发针对登革热的完全保护。
Sci Transl Med. 2016 Mar 16;8(330):330ra36. doi: 10.1126/scitranslmed.aaf1517.
5
A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.一种基于登革病毒2型主干的重组嵌合四价登革热候选疫苗。
Expert Rev Vaccines. 2016;15(4):497-508. doi: 10.1586/14760584.2016.1128328. Epub 2016 Feb 22.
6
Immune correlates for dengue vaccine development.登革热疫苗研发的免疫相关因素
Expert Rev Vaccines. 2016;15(4):455-65. doi: 10.1586/14760584.2016.1116949. Epub 2015 Nov 24.
7
Dengue human infection models to advance dengue vaccine development.用于推进登革热疫苗研发的人类登革热感染模型。
Vaccine. 2015 Dec 10;33(50):7075-82. doi: 10.1016/j.vaccine.2015.09.052. Epub 2015 Sep 28.
8
Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.在登革热流行地区,一种登革热疫苗的有效性和长期安全性。
N Engl J Med. 2015 Sep 24;373(13):1195-206. doi: 10.1056/NEJMoa1506223. Epub 2015 Jul 27.
9
Human CD8+ T-Cell Responses Against the 4 Dengue Virus Serotypes Are Associated With Distinct Patterns of Protein Targets.人类针对4种登革病毒血清型的CD8 + T细胞反应与不同的蛋白质靶标模式相关。
J Infect Dis. 2015 Dec 1;212(11):1743-51. doi: 10.1093/infdis/jiv289. Epub 2015 May 15.
10
Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults.对健康、未感染黄病毒的成年人单剂量接种减毒活四价登革热疫苗后,对所有4种登革热病毒血清型产生稳健且平衡的免疫反应。
J Infect Dis. 2015 Sep 1;212(5):702-10. doi: 10.1093/infdis/jiv082. Epub 2015 Mar 22.

与rDEN2Δ30(汤加/74)实验性感染相关的细胞免疫模式支持其作为人类登革病毒攻击株的适用性。

Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2Δ30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain.

作者信息

Grifoni Alba, Angelo Michael, Sidney John, Paul Sinu, Peters Bjoern, de Silva Aruna D, Phillips Elizabeth, Mallal Simon, Diehl Sean A, Botten Jason, Boyson Jonathan, Kirkpatrick Beth D, Whitehead Stephen S, Durbin Anna P, Sette Alessandro, Weiskopf Daniela

机构信息

Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California, USA.

Genetech Research Institute, Colombo, Sri Lanka.

出版信息

J Virol. 2017 Mar 29;91(8). doi: 10.1128/JVI.02133-16. Print 2017 Apr 15.

DOI:10.1128/JVI.02133-16
PMID:28148797
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5375662/
Abstract

A deletion variant of the dengue virus (DENV) serotype 2 (DENV2) Tonga/74 strain lacking 30 nucleotides from its 3' untranslated region (rDEN2Δ30) has previously been established for use in a controlled human DENV challenge model. To evaluate if this model is appropriate for the derivation of correlates of protection for DENV vaccines on the basis of cellular immunity, we wanted to compare the cellular immune response to this challenge strain to the response induced by natural infection. To achieve this, we predicted HLA class I- and class II-restricted peptides from rDEN2Δ30 and used them in a gamma interferon enzyme-linked immunosorbent spot assay to interrogate CD8 and CD4 T cell responses in healthy volunteers infected with rDEN2Δ30. At the level of CD8 responses, vigorous responses were detected in approximately 80% of donors. These responses were similar in terms of the magnitude and the numbers of epitopes recognized to the responses previously observed in peripheral blood mononuclear cells from donors from regions where DENV is hyperendemic. The similarity extended to the immunodominance hierarchy of the DENV nonstructural proteins, with NS3, NS5, and NS1 being dominant in both donor cohorts. At the CD4 level, the responses to rDEN2Δ30 vaccination were less vigorous than those to natural DENV infection and were more focused on nonstructural proteins. The epitopes recognized following rDEN2Δ30 infection and natural infection were largely overlapping for both the CD8 (100%) and CD4 (85%) responses. Finally, rDEN2Δ30 induced stronger CD8 responses than other, more attenuated DENV isolates. The lack of a known correlate of protection and the failure of a neutralizing antibody to correlate with protection against dengue virus have highlighted the need for a human DENV challenge model to better evaluate the candidate live attenuated dengue vaccines. In this study, we sought to characterize the immune profiles of rDEN2Δ30-infected subjects and to compare the profiles with those for subjects from areas where DENV is hyperendemic. Our data demonstrate that T cell responses to rDENV2Δ30 are largely similar to those to natural infection in terms of specificity, highlighting that the response to this virus in humans is appropriate as a model for the T cell response to primary DENV2 infection.

摘要

登革病毒2型(DENV2)汤加/74株的一种缺失其3'非翻译区30个核苷酸的缺失变异株(rDEN2Δ30)先前已被构建用于可控的人类登革病毒攻击模型。为了评估该模型是否适合基于细胞免疫推导登革病毒疫苗的保护相关性,我们想将对该攻击株的细胞免疫反应与自然感染诱导的反应进行比较。为实现这一目的,我们预测了rDEN2Δ30的HLA I类和II类限制性肽,并将其用于γ干扰素酶联免疫斑点试验,以检测感染rDEN2Δ30的健康志愿者的CD8和CD4 T细胞反应。在CD8反应水平上,约80%的供体检测到强烈反应。这些反应在强度和识别的表位数量方面与先前在登革病毒高度流行地区供体的外周血单个核细胞中观察到的反应相似。这种相似性延伸到登革病毒非结构蛋白的免疫优势等级,NS3、NS5和NS1在两个供体队列中均占主导地位。在CD4水平上,对rDEN2Δ30疫苗接种的反应不如对自然登革病毒感染的反应强烈,且更集中于非结构蛋白。rDEN2Δ30感染和自然感染后识别的表位在CD8(100%)和CD4(85%)反应中大部分重叠。最后,rDEN2Δ30诱导的CD8反应比其他减毒程度更高的登革病毒分离株更强。缺乏已知的保护相关性以及中和抗体与登革病毒保护作用不相关,凸显了需要一个人类登革病毒攻击模型来更好地评估候选减毒活登革疫苗。在本研究中,我们试图描述rDEN2Δ30感染受试者的免疫特征,并将这些特征与登革病毒高度流行地区受试者的特征进行比较。我们的数据表明,T细胞对rDENV2Δ30的反应在特异性方面与对自然感染的反应基本相似,这突出表明人类对该病毒的反应适合作为T细胞对原发性DENV2感染反应的模型。